>>Signaling Pathways>> Others>>ADDA 5 hydrochloride

ADDA 5 hydrochloride

Catalog No.GC32251

ADDA 5 염산염은 시토크롬 c 산화효소(CcO)의 부분적 비경쟁적 억제제이며, 인간 신경교종 및 소 심장에서 정제된 CcO에 대해 IC50이 각각 18.93μM 및 31.82μM입니다.

Products are for research use only. Not for human use. We do not sell to patients.

ADDA 5 hydrochloride Chemical Structure

Cas No.: 473268-46-1

Size 가격 재고 수량
10mM (in 1mL DMSO)
US$92.00
재고 있음
5mg
US$83.00
재고 있음
10mg
US$142.00
재고 있음
25mg
US$313.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

ADDA 5 hydrochloride is a partial non-competitive inhibitor of cytochrome c oxidase (CcO), with IC50s of 18.93 μM and 31.82 μM for purified CcO from human glioma and bovine heart, respectively.

ADDA 5 hydrochloride is a partial non-competitive inhibitor of CcO, with IC50s of 18.93 μM and 31.82 μM for purified CcO from human glioma and bovine heart, respectively. ADDA 5 inhibits CcO activity in UTMZ and Jx22-derived GSCs, with IC50s of 21.4 ± 3.9 μM and 15.5 ± 2.8 μM. ADDA 5 (25 μM) shows a growth inhibitory effect on UTMZ cells, with an EC50 of 8.17 μM[1].

ADDA 5 (8 mg/kg, i.p.) significantly suppresses the growth of tumor in mice. ADDA 5 does not causes detectable toxicity at up to 80 mg/kg in mice[1].

[1]. Oliva CR, et al. Identification of Small Molecule Inhibitors of Human Cytochrome c Oxidase That Target Chemoresistant Glioma Cells. J Biol Chem. 2016 Nov 11;291(46):24188-24199. Epub 2016 Sep 27.

리뷰

Review for ADDA 5 hydrochloride

Average Rating: 5 ★★★★★ (Based on Reviews and 38 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for ADDA 5 hydrochloride

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.